Important Information for Intellia Therapeutics, Inc. (NTLA) Investors: Rosen Law Firm Announces Class Action Lawsuit and Lead Plaintiff Deadline
New York, April 01, 2025 – Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Intellia Therapeutics, Inc. (NASDAQ: NTLA) between July 30, 2024 and January 8, 2025, both dates inclusive (the “Class Period”), of the important April 14, 2025 lead plaintiff deadline. The lawsuit seeks to recover damages for Intellia Therapeutics investors under the Securities Act of 1933.
According to the lawsuit, during the Class Period, Intellia Therapeutics made false and misleading statements and failed to disclose material information about the company’s business, operations, and prospects. Specifically, the company reported positive results from a Phase 1/2 clinical trial of its CRISPR/Cas9 gene-editing therapy for transthyretin amyloid cardiomyopathy. However, these results were later revealed to be inaccurate, as the company had failed to disclose that some of the patients included in the trial had received placebo treatment instead of the actual therapy.
Impact on Individual Investors
If you purchased Intellia Therapeutics securities during the Class Period, you may be entitled to compensation. The lead plaintiff deadline is April 14, 2025. To obtain more information, contact Rosen Law Firm by calling (866) 767-3653 or go to
Impact on the World
The news of the class action lawsuit against Intellia Therapeutics could have significant implications for the biotech industry as a whole. It highlights the importance of transparency and accuracy in clinical trial results, as well as the need for robust regulatory oversight to ensure that investors are not misled. Furthermore, it could lead to increased scrutiny of other companies in the gene-editing space, particularly those that have reported positive clinical trial results in recent months.
However, it’s important to note that the outcome of this lawsuit is uncertain, and it could take many months or even years to be resolved. In the meantime, investors should exercise caution and carefully consider the risks and potential rewards of investing in biotech companies, particularly those that are still in the clinical trial stage.
Conclusion
In conclusion, the Rosen Law Firm’s announcement of a class action lawsuit against Intellia Therapeutics, Inc. for misleading investors during the Class Period is an important development for the biotech industry. It underscores the need for transparency and accuracy in clinical trial results, as well as the importance of regulatory oversight to protect investors. If you purchased Intellia Therapeutics securities during the Class Period, you may be entitled to compensation, and the lead plaintiff deadline is April 14, 2025. For more information, contact Rosen Law Firm at (866) 767-3653 or go to
- Intellia Therapeutics, Inc. (NASDAQ: NTLA)
- Class Action Lawsuit
- Securities Act of 1933
- July 30, 2024 to January 8, 2025 (Class Period)
- Lead Plaintiff Deadline: April 14, 2025
